ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

OPTI Optibiotix Health Plc

19.60
-1.40 (-6.67%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.40 -6.67% 19.60 20.00 20.50 21.50 20.25 21.00 572,429 16:35:01
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Noncomml Resh Organizations 457k 2.59M 0.0284 7.13 18.47M
Optibiotix Health Plc is listed in the Noncomml Resh Organizations sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix Health was 21p. Over the last year, Optibiotix Health shares have traded in a share price range of 5.75p to 43.50p.

Optibiotix Health currently has 91,190,661 shares in issue. The market capitalisation of Optibiotix Health is £18.47 million. Optibiotix Health has a price to earnings ratio (PE ratio) of 7.13.

Optibiotix Health Share Discussion Threads

Showing 32801 to 32825 of 147450 messages
Chat Pages: Latest  1314  1313  1312  1311  1310  1309  1308  1307  1306  1305  1304  1303  Older
DateSubjectAuthorDiscuss
18/1/2018
09:47
Its' a bb not a gramma skool
pglancy
18/1/2018
09:32
Someone just sold 14k shares. Of course there could be many reasons for this sale or are people just not getting the OPTI story? Asking as we really should be further forward share price wise. IMHO.
rafboy
18/1/2018
09:24
That's just Scotty taking the pis's
owenmo
18/1/2018
09:21
That's ok Judi, now just eliminate the apostrophe in "apostrophe's" and, by same token, in "comma's" and you're hunky dory; they're simple plural nouns (not noun's) yes? I'll go off watch soon.
owenmo
18/1/2018
09:18
Sa,me her,e j,j. 😁
scotty1
18/1/2018
09:06
owen,
Your very correct
I've never been very good at apostrophe's or comma's
Just chuck them in when I think they look right
:)

judijudi
18/1/2018
08:52
Judi, to relieve the tedium, to-day I'm on apostrophe-watch. Don't you mean LTHs' - being possessive and all of that.
owenmo
18/1/2018
07:59
One day the tipping point will be in LTH’s favour
Get rid of the seller/s and the few £100’s profit traders, get the buyers dominating
Then it’s Happy days

judijudi
18/1/2018
07:57
Risky,I had noticed in recent correspondence with SOH that he was mentioning microbiome modulators first, for eg in his email to primal he wrote:On top of this we have multiple opportunities developing in microbiome modulators, natural high intensity sweeteners, and sweet fibres, and approaches from a number of corporates looking at potential M&A opportunities.After the news yesterday I agree with your comment:When SOH says he's most excited about the sugars he likely means these Optibiotic prebiotic sugars and not sweetbiotix which is clearly also huge too.
parob
17/1/2018
23:53
Optis reverse enzyme technology which is able to selectively enhance the growth and thus health benefits of specific strains is game changing to this £40+bn growing market. When SOH says he's most excited about the sugars he likely means these Optibiotic prebiotic sugars and not sweetbiotix which is clearly also huge too. Most investors don't fully understand Opti yet which is allowing decent accumulation for those who understand the real potential.Opti are the only ones in the industry with this technology which is protected by patents. The technology extracts a specific sugar from a specific strain and feeds it back to the strain making it the most effective prebiotic available. Think how big the microbiome is becoming and then think of having the technology to make every probiotic on the market better by feeding it the ultimate enhancement. The LGG probiotic has completely different benefits to LPLDL so it doesn't make any sense to compare. Opti want as many companies to use this technology and take a slice of the £££ via licensing agreements from the finished products. It's the biggest breakthrough in this space to date which is why it is taking so long. Absolutely massive news with the DSM Culturelle name drop. Clearly this has worked well and will end with a commercial agreement at some point.
riskybusiness1
17/1/2018
22:30
Nobody has mentioned our new board member.
As investors we want it all now, and I accept that, but the potential here is huge.
Our new addition has been brought in to guide us through shark infested waters at a time when we are the prime cut.

With Opti no news is good news, they are patenting each and every strain and have the patent on the technology that identifies the strains so it's a bit like designing a new vehicle and being the only company that has the technology to fuel it!

I will admit to being very frustrated at the disconnection between the current market cap and the perceived value but these gaps close eventually.

Has anyone owned up to the decent buys today?

S

shrewdmole
17/1/2018
21:48
Kim Binderup is Vice President Innovation, Human Nutrition & Health at DSM.He is connected to SOH on LinkedIn.He joined DSM from Chr. Hansen in 2016!
parob
17/1/2018
21:37
Not sure of any impact for Opti but Gareth Barker, the DSM non exec on Opti’s board, has been promoted to a higher position within DSM, but now not in human nutrition. So his priorities may now have changed. Hopefully not and he might even have more influence.

“DSM has appointed Gareth Barker as president DSM Personal Care & Aroma Ingredients. Barker, a British national with a doctorate from Oxford University, UK, joined Roche/DSM in 1993 and through 2012 he held a variety of commercial and marketing positions in Switzerland, Hong Kong, Singapore and Costa Rica.

Since October 2012 he has been VP-HNH EMEA, making a significant impact on the implementation of value strategy, segment marketing and the Health Benefits Solutions platform in Human Nutrition.

In his new role, Barker is a member of the executive committee. He reports to Christoph Goppelsroeder, president & CEO, DSM Nutritional Products.“

mouse20
17/1/2018
20:22
Its worth remembers Chr Hansen acquired LGG strain from Valio for €73m cash (Sept 2016) on JUST €9m revenues or just over x8 earnings. This is just for a single strain. I wonder what LP-LDL will be worth in 3-5 years time. SweetBiotix is worth £20+ now ahead of commercial footprint.

Given today's news, it's perhaps worth recalling the following:

The key differences between the LGG strain and Optibiotix's LP-LDL®
strain are:-
a. LGG is a recognised brand and LP-LDL® is not as yet established:

Optibiotix has significantly increased its trademarks as they extend the branding internationally. This creates ‘double IP’ which is commercially attractive for companies as it gives double protection and from our point of view the potential for separately licensing the brand and IP. Optibiotix used LP-LDL® in all
company presentations and publications to start building up market and brand recognition.

b. LGG has numerous supporting scientific publications: Optibiotix have started the process of presenting and publishing the data from the LP-LDL® strain. They will also be publishing data on the mechanisms of action and potential ways of enhancing LP-LDL®’s cholesterol and blood pressure reducing effect. They will also be carrying out additional human studies in new markets with partners. These will include more patients with elevated levels of cholesterol.

c. LGG has Commercial sales. These are for general health applications and are in multiple formulations with numerous partners allowing global reach. LP-LDL® has no sales but is following a similar ‘Coffee Bean’ model where it sees its LP-LDL® in multiple applications, multiple presentations and formulations, across multiple territories. The reduces the risk of a single partner taking on the product and exploiting limited formulations in limited territories.

d. LP-LDL® has been developed using a systemic and scientific rationale after screening over 4000 strains. This gives it a stronger scientific foundation than LGG.

e. LP-LDL® has a known mechanism of action. This is important in some regulatory frameworks, particularly where there is the potential for it to be sold as a pharmaceutical product. There is no known mechanism of action for LGG. A significant value adding difference in favour of LP-LDL®.

f. LP-LDL®’s mechanism of action has numerous potential other applications including C.difficile infection, diabetes, weight management, and stress/sleep control.

g. LP-LDL® is targeted at a specific health condition. There is growing evidence the Probiotic market is moving more towards specific health conditions with health claims supported by good science (i.e. Better Science, Better Health).

h. In summary whilst we recognise LP-LDL® is at a much earlier stage of its development it has a strong scientific foundation, a growing scientific evidence base, multiple application opportunities, and growing brand recognition.

elrico
17/1/2018
20:06
Martin - The short answer is yes. For example, we have been told OPTI are in ongoing discussions with 30+ companies for a wide range of products containing, SlimBiome, LP-LDL, SweetBiotix, etc. Some will want same or similar products in the same territories. These will need to be whittled down, presumably based on commercial strategy that fits with OPTI's BOD vision.

For a detailed waffle, visit the following link. It has been fact checked by SOH, with comments, etc.

elrico
17/1/2018
20:04
Speccy's commented on OPTI in his blog today:



I'm even more excited about OPTI:Optibiotix after today's RNS that they are publishing a paper at Probiota 2018 on the identification and development of a prebiotic which selectively enhances the growth of Lactobacillus rhamnosus GG (LGG(R)) in the gut. This is the best-selling probiotic in the world! There's an existing market and all the manufacturers have to do is add the new prebiotic to enhance their existing ingredient! What baffles me is how that news only resulted in 28 trades, and most are showing as sells. Do people not understand??

parob
17/1/2018
19:48
Elrico, pgl - thanks for helpful replies.

Elrico - on q3. I suppose I am asking, with the partnership agreements, can OPTI still develop products with other partners, if opportunity arises. EG in India, with companies other than TATA?

m4rtinu
17/1/2018
19:27
Will OPTI develop a prebiotic to enhance the growth of Beneds PS128 strain?

Psychobiotics have been getting an increasing amount of coverage.

Yesterday Scott Anderson (author of the Psychobiotic Revolution) tweeted:

The word is getting out: Gut-brain axis and psychobiotics

parob
17/1/2018
15:47
I hope your right elric. I think you have nailed it.
pglancy
17/1/2018
15:41
Martin - Hopefully, Adnan's comments, as reposted by PG will assist in the NHS question. However, I would add, this is NOT a process OPTI expect to engage in at this stage. I cannot find my note as to the reason why and I don't want to misquote SOH.

Q3: I'm not sure what you mean, "Should I presume that other opportunities are restricted by this?"

elrico
17/1/2018
15:36
I would also speculate that these potential deals are at an advanced and sensitive stage, if that were not the case then I suspect SoH would have run an interview giving more insight into the RNS. Clearly he is limited to what he can say
trotterstrading
17/1/2018
15:16
PGlancy - We can only speculate at this stage. One thing is for sure, Chr Hansen, DSM and OPTI have collaborated. OPTI have been given access to LGG for a reason. OPTI have enhanced/improved LGG, a world leading probiotic. It is natural to expect there will be a progression to utilising this improvement in existing and or new probiotics. Will they be with Chr Hansen, DSM or both? It's not too much of a leap is it! The fact OPTI are presenting the abstract at ProBiota, suggests all 3 parties are very pleased with the results and want to use it to promote their wears, and demonstrate to key decision makers they are at the front of a revolution in probiotics.

Today's news is fantastic.

elrico
17/1/2018
15:00
MARTIN, Q2 from a gps perspective

adnanwolf - 14 Aug 2017 - 21:44:48 - 25833 of 30889 OptiBiotix - Better Science, Better Health. Better buy some! - OPTI
Hi re prescribing on NHS

1. Any company or distributor would apply via ACBS (Advisory committee on borderline substances)
2. They generally do not consider nutraceuticals unless specific indication and fairly robust evidence
3. I think LP LDL has a good chance of being accepted
4. Generally they would not accept a product which has a medicinal equivalent but in this case LP LDL lowers cholesterol and BP with no side effects which is fairly unique
5. I suspect a product will be on shelves while an application is in process
6. I don't think this is a statin replacement per se rather an add on or mono therapy for those intolerant to statins and a massive help in primary prevention especially for ethnic minority patients with bad genetics.
7. Remember statins have robust morbidity and mortality data whilst we can infer similar benefits this is not proven. Statins also have anti inflammatory properties that help the anti plaque forming process

adnanwolf - 10 Aug 2017 - 11:30:14 - 25618 of 30889 OptiBiotix - Better Science, Better Health. Better buy some! - OPTI
Have recommended Lactobact LDL to a couple of patients already who were asking of a natural way to reduce cholesterol as they had side effects to statins. Would be good if available directly in UK

Should be soon

Adnan

pglancy
17/1/2018
14:54
Yes i see now nick. ta

Elric, do you see lpldl being used in hansens lgg products now?

pglancy
17/1/2018
14:43
I'm still trying to learn about this company and its products; have been a holder for 3 months. A modest holding given some posters comments.

A couple of points/ questions. I'm fairly thick-skinned, so please feel free to shoot down.

1. As far as today's RNS is concerned: is this new development a way off commercialisation stage and something for the future?

2. If LP-LDL is a good replacement for statins; indeed a GP posts occasionally about it. What would it take for GPs to start prescribing/ recommending it? Or put another way, how does a product get on the NHS's book?

3. OPTI has chosen to go down the partnership route, eg TATA, CII etc. The benefits being making use of large companies' infrastructure. Should I presume that other opportunities are restricted by this?

Thnaks MU

m4rtinu
Chat Pages: Latest  1314  1313  1312  1311  1310  1309  1308  1307  1306  1305  1304  1303  Older

Your Recent History

Delayed Upgrade Clock